Press releases

Pharmaleads Presents New Data Showing DENKIs, a New Class of Painkillers, to be Devoid of Abuse Potential and Opiate Side-Effects

Clinical and preclinical data demonstrating efficacy, safety and tolerability presented at the Annual International Conference on Opioids in Boston Paris, France, 11 June  2018 – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, today announced new clinical and preclinical data showing the efficacy, safety and […] Read full post »

Published on June 11, 2018

DENKI (Dual ENKephalinase Inhibitors), a new class of painkillers devoid of abuse potential and of opiate side-effects

Published on June 11, 2018

Pharmaleads to present at BioTrinity 2018 in Lontodon

Paris, France, [19 April 2018] – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, will present at BioTrinity 2018 in Lontodon on Tuesday, April 24th at 3.35pm. Michel Wurm, VP Medical Affairs, will introduce Pharmaleads and its innovative compounds, PL265 and PL37, which protect enkephalins, […] Read full post »

Published on April 19, 2018